Cytek® Biosciences Names William McCombe Chief Financial Officer
- None.
- None.
Insights
The appointment of William McCombe as CFO of Cytek Biosciences represents a strategic move for the company, particularly in light of his extensive background in finance and operations within technology companies. McCombe's track record in mergers and acquisitions (M&A) and capital markets indicates a potential future strategy for Cytek to pursue growth through these avenues. His expertise could facilitate more efficient financial management and possibly attract investor confidence, which may have a positive effect on Cytek's stock performance.
Furthermore, the reaffirmation of Cytek's 2024 revenue guidance suggests stability and confidence in the company's financial projections. The expected positive net income indicates operational efficiency and could signal to investors that the company is on a sustainable growth trajectory. However, the projected 5% to 10% revenue growth is modest and may not excite investors looking for high-growth opportunities. It is also important to note that these projections assume stable currency exchange rates, which are subject to volatility and could impact financial outcomes.
From a market perspective, Cytek's positioning as a leader in cell analysis solutions is noteworthy. The sector is competitive and rapidly evolving, with significant R&D investments driving innovation. McCombe's background in high-growth technology companies and his experience with public company dynamics could be advantageous in navigating this landscape. His strategic approach to finance could lead to enhanced market positioning and competitive edge for Cytek.
It is essential to monitor how McCombe's leadership will influence Cytek's market strategies, including potential M&A activities, which could reshape the company's market share and competitive standing. The reaffirmed outlook also provides a benchmark for evaluating the company's performance against market expectations. Any deviation from this guidance in future quarters could influence market sentiment and investor behavior.
McCombe's legal background, with degrees in law and commerce, may provide Cytek with additional expertise in navigating the complex regulatory environment of biotechnology and healthcare. His experience could prove valuable in managing compliance and legal risks associated with M&A, intellectual property and international operations. This legal acumen, combined with his financial expertise, may contribute to a more strategic and holistic approach to corporate governance and risk management.
Investors should consider the potential implications of McCombe's legal and financial expertise on Cytek's ability to manage legal challenges and capitalize on strategic opportunities. Effective legal governance can enhance investor trust and potentially protect the company's market value from the adverse effects of legal disputes or regulatory issues.
Experienced executive with extensive background as CFO for global corporations across dynamic sectors
Cytek reaffirms 2024 outlook
FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-dollar revenue satellite and space imaging company.
McCombe has significant experience in financial management, public company reporting and operational finance, and a proven track record of driving growth and building high-performance teams. He also brings deep expertise in mergers, acquisitions, and capital markets transactions with a career of more than 20 years as an investment banker, where he was a Managing Director at Morgan Stanley and at Bank of America. McCombe earned an MBA from Columbia University, and Bachelor of Laws and Bachelor of Commerce degrees from the University of Melbourne.
“Bill's wealth of experience in finance, combined with his strategic approach, expertise in public company dynamics, and transformational leadership skills, uniquely positions him to drive our corporate objectives.” stated Dr. Wenbin Jiang, Cytek's Chairman and CEO. “We are confident in his ability to partner with us in steering Cytek towards sustainable growth and long-term value creation.”
“Cytek is globally recognized as a leader in cell analysis solutions,” said McCombe. “I am excited by the opportunity to join such an innovative company and play a meaningful role in charting the next chapter of the company’s continued success. I believe there is tremendous growth potential at Cytek, and I look forward to the journey ahead.”
As CFO, McCombe will lead Cytek’s global finance organization and financial activities including accounting and controllership, financial planning and analysis, tax, investor relations, internal audit, mergers and acquisitions, and treasury. McCombe will be based in Cytek’s Fremont, California headquarters.
McCombe succeeds Patrik Jeanmonod, who has been appointed as the company’s head of corporate development analytics. Jeanmonod served as Cytek’s chief financial officer since 2018.
Jiang expressed, “I would like to thank Patrik for what he has accomplished at Cytek. He has played an instrumental role in the growth of Cytek during a transformational period, developing the financial strategy and planning behind multiple transactions and programs as well as key finance initiatives. We are thankful for Patrik’s tremendous contributions to Cytek over the years and we look forward to his continued contributions under his new role.”
2024 Outlook Reaffirmed
Cytek also reaffirms its previously stated full year 2024 revenue guidance of
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding the Company’s growth, growth potential, future success and long-term value creation; and Cytek’s expectations that total revenue for the full year ended December 31, 2024 will be in the range of
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com
FAQ
Who has been appointed as the chief financial officer of Cytek Biosciences, Inc.?
What is Cytek Biosciences, Inc.'s ticker symbol?
What is Cytek Biosciences, Inc.'s 2024 revenue guidance range?
What is the expected net income status for Cytek Biosciences, Inc. for the year ended December 31, 2024?
Where will William McCombe be based as the CFO of Cytek Biosciences, Inc.?
